Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Caribou Biosciences is a biopharmaceutical company specializing in CRISPR-based genome editing to develop allogeneic cell therapies. Its core focus is on off-the-shelf CAR-T treatments for hematologic cancers and autoimmune diseases, utilizing proprietary chRDNA technology for precise, multiplex genome modifications. The company aims to enhance therapy durability, safety, and accessibility through innovative gene editing, targeting unmet medical needs in oncology and immunology markets.
This description was generated via AI from an annual report. Updated about 1 year ago.